Journal
DRUG DISCOVERY TODAY
Volume 18, Issue 23-24, Pages 1221-1227Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2013.07.011
Keywords
-
Categories
Funding
- EPSRC
- BBSRC
- Medical Research Council of the UK
- EPSRC [EP/I037288/1] Funding Source: UKRI
- MRC [G0901532] Funding Source: UKRI
- Cancer Research UK [11566] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [EP/I037288/1] Funding Source: researchfish
- Medical Research Council [G0901532] Funding Source: researchfish
Ask authors/readers for more resources
The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs. As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science. The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available